Aventa™ Genomics, LLC, a clinical laboratory specializing in 3D genomics to enhance patient outcomes and a wholly-owned subsidiary of Arima Genomics, Inc., announced today that it has received a favorable final pricing decision for the 2025 Centers for Medicare and Medicaid Services (CMS) Clinical Laboratory Fee Schedule (CLFS). This determination applies to the Aventa FusionPlus test, a next-generation sequencing assay that detects gene fusions, translocations, and rearrangements in solid tumors using formalin-fixed, paraffin-embedded (FFPE) tissue samples.
Aventa Genomics, LLC, a leader in 3D genomics technology, has received favorable final pricing for its Aventa FusionPlus test under the 2025 Centers for Medicare and Medicaid Services (CMS) Clinical Laboratory Fee Schedule (CLFS). This test, which is part of the company’s broader mission to enhance patient outcomes, uses cutting-edge 3D genomics to detect gene fusions, translocations, and rearrangements in solid tumors from formalin-fixed, paraffin-embedded (FFPE) tissue samples. This pricing determination is a significant milestone in the journey to make the test more accessible to clinicians and patients.
The Aventa FusionPlus test distinguishes itself by leveraging the spatial proximity of fused and rearranged genes, amplifying the signal by 100- to 1000-fold. This innovation allows for the identification of novel breakpoints and fusion partners, offering a deeper level of insight than traditional methods like RNA sequencing and fluorescent in situ hybridization (FISH). While these conventional techniques can detect some biomarkers, they often miss others, which the Aventa FusionPlus test can identify. This enhanced capability is essential for providing a more comprehensive assessment of cancer, particularly for tumors with complex genetic changes.
Chris Roberts, Executive Director of Aventa Genomics, emphasized the importance of CMS’s favorable pricing decision, stating, “This determination highlights the importance of innovation in cancer diagnostics and enables us to continue to expand clinician access to our novel 3D genomics-based test.” He further noted that the integration of the Aventa FusionPlus test into the diagnosis and management of patients with solid tumors would ultimately lead to improved patient outcomes.
Earlier this year, the Aventa FusionPlus test was granted a Proprietary Laboratory Analysis (PLA) code, which is a key step in the process for gaining reimbursement from Medicare. The test also received initial pricing from its Medicare administrative contractor, First Coast Service Options, Inc. The CLFS pricing for the Aventa FusionPlus test will be effective starting January 1, 2025. Additional information and test requisition forms for healthcare providers are available on Aventa Genomics’ website.
Aventa Genomics, a wholly-owned subsidiary of Arima Genomics, Inc., is committed to improving patient outcomes by applying 3D genomics tools to uncover druggable targets and resolve complex diagnostic challenges. The company’s first laboratory-developed test, Aventa FusionPlus, allows physicians to detect gene fusions, translocations, and rearrangements in solid cancers, offering an advanced approach to precision oncology. Healthcare providers can order the test through Aventa Genomics’ website.
Arima Genomics, Inc., the parent company of Aventa Genomics, is at the forefront of advancing human health through the use of innovative genomic technologies. By providing deep insights into the three-dimensional organization of the genome, Arima Genomics helps researchers and clinicians gain a better understanding of disease mechanisms, identify biomarkers, and develop new therapeutic approaches.
